Sino Biopharmaceutical Limited (HKG: 1177) announced in a voluntary filing that clinical results for TQ‑A3334, an oral TLR7 agonist independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), have been selected as a “Late‑Breaking Abstract” (LBA) with an oral presentation at The Liver Meeting 2026 of the American Association for the Study of Liver Diseases (AASLD), while bepirovirsen, the antisense oligonucleotide (ASO) from the strategic collaboration between CTTQ and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations, including one poster of distinction.
Conference Milestone
| Item | Detail |
|---|---|
| Company | Sino Biopharmaceutical Limited (HKG: 1177) |
| Developer | CTTQ (subsidiary); bepirovirsen via CTTQ–GSK strategic collaboration |
| Congress | The Liver Meeting 2026 – AASLD |
| Assets Featured | TQ‑A3334 (TLR7 agonist) and bepirovirsen (ASO) |
| TQ‑A3334 Selection | Late‑Breaking Abstract (LBA) – oral presentation |
| Bepirovirsen Selection | 2 orals + 8 posters (incl. 1 poster of distinction) |
| Indication Focus | Chronic hepatitis B (CHB) – functional cure |
AASLD 2026 Presentation Schedule
| Slot | Asset | Abstract | Presenter | Date, Time & Venue |
|---|---|---|---|---|
| Late‑Breaking Oral (LBA) | TQ‑A3334 | Efficacy and safety of an oral TLR7 agonist through 48 weeks in NAs‑treated chronic HBV infection – randomized, double‑blind, placebo‑controlled Phase II trial | Prof. Hong Tang, West China Hospital of Sichuan University | 8 Nov 2026, 5:30–5:45 pm (local); Late Breaking Abstract Parallel Session 2 |
| Oral #1 | Bepirovirsen | Rates of functional cure in participants with chronic HBV treated with bepirovirsen – B‑Well Phase 3 trials end‑of‑study results | Man‑Fung Yuen, The University of Hong Kong | 7 Nov 2026, 11:00–11:15 am (local); Convention Center, Bluebird Ballroom 1C |
| Oral #2 | Bepirovirsen | Bepirovirsen B‑Well Phase 3 trials – predicting functional cure rates based upon HBsAg at Week 12 | Pietro Lampertico, University of Milan | 7 Nov 2026, 11:15–11:30 am (local); Convention Center, Bluebird Ballroom 1C |
| Poster of Distinction | Bepirovirsen | Up to 15 months durability of functional cure in B‑Well responders enrolled into B‑Sure | Edward Gane, University of Auckland | Date/time not disclosed |
Both oral sessions fall under the topic “Functional Cure and Novel Therapeutics in Chronic Hepatitis B.” Full data will be released at the congress; results were not disclosed in the announcement.
Drug Profiles & Mechanisms of Action
TQ‑A3334 (TLR7 agonist)
- Classification: National Category 1 innovative drug, independently developed by CTTQ.
- Molecule: Oral, selective Toll‑like receptor 7 (TLR7) agonist.
- Mechanism: Reshapes the immune response against HBV by activating innate and adaptive immune pathways and inducing interferon and cytokine responses.
- Role in Therapy: Complements the direct antiviral effects of nucleos(t)ide analogues (NAs) – a significant exploration toward functional (clinical) cure of CHB.
Bepirovirsen (ASO)
- Molecule: Investigational triple‑action antisense oligonucleotide.
- Mechanism: Designed to inhibit viral DNA replication, suppress HBsAg levels in blood, and stimulate the immune system to increase the chances of a durable, sustained response.
- Regulatory Recognition – Japan: Approved for marketing by Japan’s MHLW in August 2026.
- Regulatory Recognition – US: Granted Fast Track, Priority Review, and Breakthrough Therapy designations by the FDA.
- Regulatory Recognition – China: Included in Breakthrough Therapy Designation and priority review and approval procedures by the CDE of NMPA.
Market Impact & Outlook
- Functional Cure Race: With bepirovirsen already commercially approved in Japan and B‑Well Phase 3 end‑of‑study results due at AASLD, the program is among the most advanced worldwide in the pursuit of CHB functional cure.
- Combination Logic: TQ‑A3334’s immune‑modulating mechanism complements NAs and, by extension, the broader curative‑strategy landscape – positioning Sino Biopharmaceutical across both antiviral‑gene‑silencing and immunomodulatory modalities.
- Dual‑Asset Showcase: The scale of AASLD acceptance – an LBA for TQ‑A3334 plus 10 bepirovirsen presentations – underscores the global scientific standing of the CTTQ–GSK collaboration and Sino Biopharmaceutical’s hepatology pipeline.
- Data Catalysts: The 7–8 Nov presentations (functional cure rates, HBsAg‑based Week 12 prediction, 15‑month durability) represent near‑term catalysts; specific efficacy figures have not yet been disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical data to be presented at AASLD 2026, regulatory timelines, and development and commercialization expectations for TQ‑A3334 and bepirovirsen. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions in various jurisdictions, and competitive dynamics in the hepatitis B therapeutic market.-Fineline Info & Tech
